The Antidote: Inside the World of New Pharma (84 page)

future of,
249
,
259
,
314
–15,
321
–23,
385
–88

honors of,
320
–21

image, identity, and reputation of,
11
,
30
,
41
,
49
–50,
133
,
160
,
243
,
275
,
278
–80,
365
,
369

launch of,
1
,
5
,
7

lawsuits of,
48
,
75
–76,
101

layoffs at,
88
–91,
94
–96

mission of,
41
,
117
,
133
,
146
,
196
–97,
205
,
281
,
286

mock AdComms and,
227
,
228
,
230
,
243
-44,
255
–56

morale at,
335
,
356
,
379

as operating company,
218
–19,
281
,
379

partnerships of,
12
–13,
18
,
25
–27,
31
–32,
44
,
47
–49,
51
–53,
56
–59,
61
–66,
68
,
72
,
75
–78,
82
–83,
85
,
87
–88,
97
–99,
101
–2,
105
–8,
111
,
114
,
142
,
144
–45,
149
,
169
–70,
172
–73,
177
–78,
186
,
193
,
206
,
215
–16,
239
,
299
–300,
326
,
336
,
347
,
370
,
375
,
378
,
380

physical expansions of,
58
,
85
,
87
–88,
240
,
320

portfolio process of,
90
–95,
97
–101,
105

project councils of,
18
–19,
25
,
27
–28

reorganizations of,
59
–60,
64
–65,
333
–37

reporting structure of,
59
,
64
–65,
71
,
122
,
144
,
201
,
207
,
333
–34

rivalries of,
1
,
7
,
14
,
16
,
19
,
101
,
110
,
207
,
249
,
260
–62,
276
,
278
,
282
,
286
,
291
–92,
307
,
316
,
347
–48

secrecy of,
25
–26,
30

slogans of,
160
,
279

strategy-opportunity balance of,
314
–15,
317

succession at,
122
–23,
143
–44,
146
,
164
–65,
188
–90,
195
–98,
205
,
331
,
338
–39,
357
–61,
363

as takeover target,
56
–57,
197
,
216
–17,
247
,
331
–33,
355
,
357
,
374

as unique and exceptional,
53
–54,
90
,
196
–97,
281
,
316
,
374

vision of,
6
,
57
,
86
,
108
,
117
,
135
,
160
,
201
,
215
,
259
,
277
,
321
–23,
377

Werth’s access to,
6
,
386
–87

“Vertex Pharmaceuticals” (Porges),
97

Vertex swoosh,
131
,
136
,
139
,
144
–46,
151
,
180
,
248
–49,
281
,
283
,
296

Vertex Vision Process,
117
,
387

Viagra,
46
,
65
,
246
,
315

Victrelis (boceprevir):

AdComm and,
264
–68,
273
,
275
–76,
299

approvals of,
266
–68,
283
,
299
,
341
–42

comparisons between Incivek and,
260
,
282
–84,
288
,
307
,
315
–16

FDA and,
264
–67,
273
,
275
–76,
283

HCV and,
172
,
200
,
208
,
212
,
228
–31,
238
,
245
,
260
,
263
–68,
273
,
275
–77,
282
–88,
299
,
307
,
311
,
315
–16,
341
–42,
354
,
374

label of,
283
,
285
,
299

Merck-Roche partnership and,
284
,
287
–88

NDA and,
228
–29,
231

patient advocates and,
266
,
273
,
275

prices and,
283
–84,
286
,
342

sales and,
277
,
284
–85,
288
,
299
,
307
,
315
–16,
342

side effects of,
267
,
283

sustained viral response (SVR) rates of,
266
,
282

Vioxx,
121
–22,
228
,
238
,
245
,
261
,
279
,
284

ViroChem,
199
,
220
,
299

Vision into Practice (VIP),
133
–35,
157
–59,
168

vorapaxar,
245

VX-148,
93

VX-175,
see
Lexiva

VX-222,
199
,
215
,
220
,
262
,
299
–300,
325
,
347
,
355
,
358
,
362
–63,
383

VX-328,
18
–19

VX-330,
18
–20,
25

VX-478,
see
Agenerase

VX-497,
see
merimepodib

VX-509,
317
–18,
380

VX-661,
251
,
363
–64,
372
,
381
–82

VX-702,
92
–93

VX-740,
see
pralnacasan

VX-745,
53
,
55
–56,
71
–75,
87
,
92
,
277

VX-765,
92
–93,
215
–16

VX-770,
see
Kalydeco

VX-787,
380

VX-809 (lumacaftor):

CF and,
155
,
177
,
180
–81,
183
,
215
,
251
,
295
–99,
301
–2,
343
,
364
–65,
367
–72,
380
–81

combining Kalydeco and,
295
–99,
301
–2

in human testing,
180
,
183
,
215
,
295
–98,
302

VX-950,
see
Incivek

Waksal, Sam,
216

Wall Street Journal
,
121
–22,
179
,
193

Warner-Lambert Company,
80
,
195

Washington retroviral conference,
25
–26,
30
–31

Webvan,
55

Weet, Jack,
267

background of,
207
–8,
227

CF and,
327
,
336

EPO and,
208
–9

Incivek and,
200
,
207
–8,
222
–23,
227
–29,
232
–33,
238
,
240
,
243
–44,
257
–58,
265
,
270
,
272
,
289
,
336

NDAs and,
207
,
222
–23,
227
–29,
232
–33,
238
,
244
,
336

weight gain, weight loss,
248
–49,
254
,
364

Weisman, Robert,
360

Werber, Yaron,
222
,
308
,
332
,
344

Williams, Brian,
263

Wilson, Keith,
29

Wokasch, Michael,
385

Wolfe, Tom,
6
,
346

World War II,
3
,
151
–52

Wright, Christopher:

CF and,
295
–96,
327
,
367
–68,
371

Mueller’s reorganizing and,
334
,
336

WuXi PharmaTech,
173
–74,
239

Wyeth,
195
,
199
–200

Wysenski, Nancy,
311
,
322

CF and,
218
,
295
,
297
,
361

Cozzolino’s resignation and,
241
–42

earnings calls and,
339
–41

Emmens’s relationship with,
210
–11,
218
,
370

HCV and,
213
,
351
–52,
357

Incivek and,
212
–14,
217
–18,
222
,
228
–29,
240
–41,
264
–65,
272
,
285
–87,
292
,
339
–42

management style and skills of,
210
–11,
218
–19,
224

Merck-Roche partnership and,
284

Merck’s AdComm presentation and,
265
–66

NDA and,
228
–29

relationship between board and,
211
,
218

Xconomy,
193
,
199
,
220
,
318
,
360

XPrize Foundation,
153
–55

yellow fever,
22

Zantac,
46

Zenobia
(Emmens and Kephart),
187
–88

Zuccotti Park, occupation of,
328

ZymoGenetics,
193

Simon & Schuster
1230 Avenue of the Americas
New York, NY 10020
www.SimonandSchuster.com

Copyright © 2014 by Barry Werth

All rights reserved, including the right to reproduce this book or portions thereof in any form whatsoever. For information, address Simon & Schuster Subsidiary Rights Department, 1230 Avenue of the Americas, New York, NY 10020.

First Simon & Schuster hardcover edition February 2014

SIMON & SCHUSTER and colophon are registered trademarks of Simon & Schuster, Inc.

The Simon & Schuster Speakers Bureau can bring authors to your live event. For more information or to book an event, contact the Simon & Schuster Speakers Bureau at 1-866-248-3049 or visit our website at
www.simonspeakers.com
.

Interior design by Kyoko Watanabe
Jacket design by Christopher Lin
Jacket photograph by Lauren Burke/Getty Images

Library of Congress Cataloging-in-Publication Data

Werth, Barry.

 The antidote : inside the world of new pharma / Barry Werth. — First Simon & Schuster hardcover edition.

  p. cm. Includes index.

 1. Vertex Pharmaceuticals Incorporated. 2. Drug Industry—United States.  3. Drug Industry—history—United States. 4. History, 20th Century—United States. 5. History, 21st Century—United States. 6. Technology, Pharmaceutical—United States. I. Title.

 RA401.A3

 338.4'76151—dc23

2013039646

ISBN 978-1-4516-5566-7
ISBN 978-1-4516-5569-8 (ebook)